Penumbra (PEN) Change in Account Payables (2014 - 2026)
Penumbra's (PEN) quarterly Change in Account Payables came in at $9.0 million in Q1 2026, up 3672.11% year-on-year from $237691.8 in Q1 2025, and up 97.58% on a QoQ basis from $4.5 million in Q4 2025.
Penumbra (PEN) Change in Account Payables (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Change in Account Payables data on file, last reported at $9.0 million in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 3672.11% year-over-year to $9.0 million in Q1 2026; TTM through Mar 2026 was $12.3 million, a 1053.73% increase from a year earlier, with the FY2025 full-year figure at $3.1 million, down 26.49% from the prior year.
- Change in Account Payables for Q1 2026 stood at $9.0 million, up from $4.5 million in the prior quarter.
- Over the last five years, Change in Account Payables for PEN reached as high as $9.0 million in Q1 2026 and fell as low as -$3.2 million in Q2 2025.
- Historically, Change in Account Payables has averaged $1.8 million across 5 years, with a median of $1.4 million in 2022.
- Across the five-year window, Change in Account Payables tumbled 1248.06% in 2025 and jumped 3672.11% in 2026, its largest moves.
- Year by year, Change in Account Payables stood at $295000.0 in 2022, then slumped by 424.41% to -$957000.0 in 2023, then slumped by 94.67% to -$1.9 million in 2024, then jumped by 343.59% to $4.5 million in 2025, then surged by 97.58% to $9.0 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $9.0 million in Q1 2026, $4.5 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -198.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 221.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 8.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.97 Mn |
| Mar 31, 2026 | 8.97 Mn |
| Dec 31, 2025 | 4.54 Mn |
| Dec 31, 2025 | 4.54 Mn |
| Sep 30, 2025 | 2.03 Mn |
| Sep 30, 2025 | 2.03 Mn |
| Jun 30, 2025 | -3.25 Mn |
| Jun 30, 2025 | -3.25 Mn |
| Mar 31, 2025 | -251,000.00 |
| Mar 31, 2025 | -251,000.00 |
| Dec 31, 2024 | -1.86 Mn |
| Dec 31, 2024 | -1.86 Mn |
| Sep 30, 2024 | 543,000.00 |
| Sep 30, 2024 | 543,000.00 |
| Jun 30, 2024 | 283,000.00 |
| Jun 30, 2024 | 283,000.00 |
| Mar 31, 2024 | 5.21 Mn |
| Mar 31, 2024 | 5.21 Mn |
| Dec 31, 2023 | -957,000.00 |
| Dec 31, 2023 | -957,000.00 |